The immune checkpoint molecules B7-H3 and B7-H4 have emerged as promising therapeutic targets in ovarian cancer, offering a new avenue to address the persistent challenges of immune evasion and treatment resistance. This evidence concerns the gene VTCN1 and ovarian carcinoma.